期刊
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
卷 22, 期 1, 页码 1-10出版社
ADIS INT LTD
DOI: 10.1007/s40257-020-00572-6
关键词
-
类别
Several strategies have been explored to overcome resistance mechanisms to BRAF/MEK inhibition in melanoma, including changing dosing regimens, adding other kinase inhibitors, and using anti-PD-1 immunotherapy in combination therapy.
About half of all cutaneous melanomas harbor activating mutations in the BRAF oncogene. Dependence on this pathway makes the tumors vulnerable to BRAF (and downstream MEK) inhibition, and three drug combinations are approved to target this vulnerability in advanced melanomas with BRAFV600 mutations. Responses to BRAF/MEK inhibitors are usually fast, but durability of response can be limited. Five-year data from BRAF/MEK inhibitors show long-term survival benefit for a third of the patients. There is a wide variety of known mechanisms of resistance to BRAF/MEK inhibition, such as mitogen-activated protein kinase reactivation, activation of parallel pathways, alterations in cell-cycle regulation, and non-genetic resistance mechanisms. Strategies that have been explored to overcome these mechanisms include alternative dosing regimens, addition of another kinase inhibitor, and use of anti-PD-1 immunotherapy either in combination or post-relapse on BRAF/MEK inhibitor therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据